Cart is empty The DAPPER study was conducted with the National Cardiovascular Center as the principal investigator, with 294 patients participating from 18 facilities in Japan. In this study, researchers investigated whether dapagliflozin suppresses urinary albumin excretion, a sensitive marker of kidney damage, and whether it also suppresses cardiovascular events in patients with chronic heart failure and type 2 diabetes mellitus.
Leave A Comment